[New drugs in the treatment of multiple myeloma]
Albert Oriol1, Cristina Motlló1
1Servicio de Hematología clínica y Unidad de investigación Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, España.
Abstract:
Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications. New drugs have been developed including new alkylating agents, proteasome inhibitors and immunomodulators but also monoclonal antibodies and drugs with new mechanisms of action. Hopefully, this new generation of targeted agents will improve the results of the initial therapy, avoid relapses and development of resistances and provide better and less toxic options for the relapsed and refractory patient.
Insights
Despite advances, multiple myeloma treatments face resistance, leading to patient mortality. New targeted therapies offer hope for improved outcomes and better options for relapsed patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Context:
- Multiple myeloma treatment has seen progress, but drug resistance remains a significant challenge.
- Most patients with multiple myeloma eventually succumb to the disease or its complications.
- Despite new drug classes, relapses and resistance are common.
Purpose:
- To review recent advancements in multiple myeloma therapeutics.
- To highlight the development of novel agents targeting multiple myeloma.
- To discuss the potential of new drugs in overcoming treatment resistance.
Summary:
- Recent decades have seen the development of novel agents for multiple myeloma, including alkylating agents, proteasome inhibitors, immunomodulators, and monoclonal antibodies.
- These new drugs offer diverse mechanisms of action, aiming to improve initial therapy effectiveness.
- The focus is on agents that can prevent relapses and overcome acquired drug resistance.
Impact:
- New targeted therapies hold promise for improving patient survival and quality of life.
- These agents may offer better and less toxic treatment alternatives for relapsed and refractory multiple myeloma.
- Advancements aim to shift the paradigm from disease delay to long-term remission and cure.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Drugs that Stabilize Microtubules
02:56Treatment Resistent Cancers